Back to CVE records
Medium 5.5Published Feb 4, 2026

CVE-2026-25145melange has a path traversal in license-path which allows reading files outside workspace

Updated under an hour ago ()

Does this affect you?

It affects chainguard-dev melange and 1 other product. Add what you run to find out whether that includes you.

No exploitation reported and no EPSS estimate yet.

melange allows users to build apk packages using declarative pipelines. From version 0.14.0 to before 0.40.3, an attacker who can influence a melange configuration file (e.g., through pull request-driven CI or build-as-a-service scenarios) could read arbitrary files from the host system. The LicensingInfos function in pkg/config/config.go reads license files specified in copyright[].license-path without validating that paths remain within the workspace directory, allowing path traversal via ../ sequences. The contents of the traversed file are embedded into the generated SBOM as license text, enabling exfiltration of sensitive data through build artifacts. This issue has been patched in version 0.40.3.

CVSS
5.5 MEDIUM (v3.1, CNA)CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:N/A:N
Weakness (CWE)
CWE-22
Known exploited
Not in CISA's KEV catalog
EPSS (exploitation in the next 30 days)
Not loaded for this CVE
Assigned by
GitHub_M
NVD analysis
Analyzed
Record last updated
Feb 5, 2026
First seen by InfoSec Signals
Oct 9, 2026

Affected products

Affected products
chainguard-dev melange
chainguard_dev:melange (from the name)
from 0.14.0, < 0.40.3
CNA record
chainguard melange
chainguard:melange
from 0.14.0 before 0.40.5
NVD

References

References

The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.

Your cookie choices
We use essential cookies to run this site, and, only with your consent, an advertising cookie from Google to measure whether our ads lead to sign-ups and subscriptions. See our for details.